EGFR tyrosine kinase inhibitors (TKIs) are currently the standard-of-care in first line therapy for patients with mutant EGFR NSCLC, with new generations of TKIs developed for patients with acquired resistance to the first and second generation TKIs [4]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.